If you look at the way financial data platforms are currently grouping stocks in the Hong Kong market, you will often find a bizarre mix of companies lumped under the umbrella of &#34;manufacturing and machinery.&#34; It is a convenient label for algorithms, but a deeply flawed one for anyone trying to understand the actual economy in 2026. This matters because it masks a profound structural divergence: the old industrial categories are shattering, and the companies within them are experiencing entirely different realities.I'm told that over the past few months, institutional capital has aggressively moved away from these broad sector ETFs. Instead, they are digging into the granular details of the supply chain, looking for specific monopolies that can ride the next massive wave of technological deployment. The true winners in this so-called physical economy are those who have quietly positioned themselves as indispensable bottlenecks for next-generation platforms.Take JL MAG Rare-Earth (6680.HK). On paper, it sounds like an old-school metal processing business. But the truth is, this company has become a critical piece of infrastructure for the booming robotics and AI hardware ecosystems. Recent guidance for the first half of 2026 points to a net profit of up to RMB 460M, marking a year-over-year surge of as much as 50.84%. More importantly, revenue from its robotics and industrial servo motor segment skyrocketed by roughly 90%. They are already doing small-batch deliveries of motor rotors for humanoid robots. It is no wonder that in early July 2026, JPMorgan Chase increased its stake by 1.25M shares. This is not traditional manufacturing; it is the physical manifestation of the AI boom.And yet, merely being in the &#34;hard assets&#34; business is no guarantee of a smooth ride in the public markets right now. Just look at the abrupt halt in the logistics space. On July 8, 2026, Yongkang Holdings (2523.HK), the largest container depot operator in Singapore with a 16.2% market share, stunned the street by announcing it would not proceed with its global offering on the Hong Kong Stock Exchange, choosing to refund all application monies. What makes this wild is that market chatter indicated the retail portion of the IPO was oversubscribed by nearly 9,000 times. To pull the plug amid that kind of retail frenzy suggests that institutional underwriters and management saw immense, unresolvable friction regarding long-term valuation in a highly volatile global trade environment.At the same time, the definition of advanced manufacturing capacity is expanding to include deep biotech infrastructure. Lepu Biopharma-B (2157.HK) perfectly illustrates this shift. As an innovative oncology company with a fully integrated ADC (antibody-drug conjugate) platform, they are proving that controlling the manufacturing process from end to end is just as crucial as the underlying science. In March 2026, their partnered ADC candidate CMG901 triggered a massive USD 45M milestone payment, of which Lepu gets USD 13.5M. With their core drug MRG003 recently securing IND approval for combination therapy, and a 2025 net profit exceeding RMB 200M, they are actively producing the next generation of healthcare hardware.The truth, as usual, is more complicated, especially for those legacy giants struggling to pivot. The ordeal of China Traditional Chinese Medicine (0570.HK) serves as a grim reminder of how brutal structural transitions can be. Battered by the centralized volume-based procurement (VBP) policies that took effect in 2023, the company saw its product prices slashed by an average of 50.77%. The fallout was devastating: the former industry titan, which once commanded a 53% market share, posted a staggering net loss of RMB 342M in 2025. While management is scrambling to transition toward innovative drugs, successfully launching two classical formulas in May 2026, pivoting a ship of this size against immense regulatory headwinds is an agonizing process.My view is that attempting to analyze these companies through the outdated lens of a monolithic &#34;manufacturing sector&#34; is a fool's errand. We are witnessing a ruthless bifurcation. If your operations are deeply embedded in the supply chains of AI, robotics, or cutting-edge biotech, the market will reward you handsomely. But if you are trapped in legacy markets fighting over dwindling margins in the face of brutal state procurement? Good luck with that.This article does not constitute investment advice.

02157

02523

06680

The broad bucket of "manufacturing and traditional sectors" is increasingly meaningless. From scrapped IPOs despite 9,000x oversubscription to magnet makers powering humanoid robots, the reality on the ground is far more fragmented and complex than the old indices suggest.

The Great Unbundling: Why Hong Kong's Manufacturing Sector is Breaking Down